Objective: To determine the prevalence and risk factors of female sexual dysfunction (FSD) among healthcare personnel in selected healthcare facilities in Malaysia.
Methods: This was a cross-sectional study carried out at three large healthcare facilities that were selected by convenience sampling. Within each facility, stratified random sampling was used to select suitable candidates to participate in the study (n=201). Validated questionnaires were used to assess depression, anxiety, sexual function in women and erectile dysfunction (ED) in their partners.
Results: The prevalence of FSD was 5.5%. Women with sexual dysfunction were more likely to be married longer (OR=4.08; 95% CI; 1.15-4.50), had lower frequency of sexual intercourse (OR=5.00; 95% C; 1.05-23.76) and had a spouse with ED (OR=24.35; 95% CI; 4.55-130.37). Multivariate analysis showed that ED was the strongest predictor for FSD (AOR=27.30; 95% CI; 4.706-159.08).
Conclusion: One in eighteen female healthcare personnel suffered from FSD and presence of ED in the partner strongly impacted her sexual function, negatively. The findings highlight the importance of including the male partner in clinical assessment of FSD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.comppsych.2013.01.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Persistent Genital Arousal Disorder/Genito-Pelvic Dysesthesia (PGAD/GPD): From Diagnostic Approach to Treatment - A Narrative Review.
J Sex Marital Ther
January 2025
Department of Obstetrics and Gynaecology, Hospital Metropolitano Odilon Behrens, Belo Horizonte, Brazil.
Persistent Genital Arousal Disorder/Genito-Pelvic Dysesthesia (PGAD/GPD) is characterized by persistent or recurrent unwanted genital arousal, causing significant distress to the affected individual. Classified as a sexual dysfunction, PGAD/GPD is predominantly described in women and severely affect their quality of life with psychological repercussions. Despite its morbidity, PGAD/GPD remains unfamiliar to healthcare professionals.
View Article and Find Full Text PDFWho is a candidate at the initial presentation? Prediction of positive lateral lymph node and survival after dissection.
Tech Coloproctol
January 2025
Department of Colorectal Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpodearo, Seochogu, Seoul, 06591, Korea.
Metastatic lateral pelvic lymph node (LPN) in rectal cancer has a significant clinical impact on the prognosis and treatment strategies. But there are still debates regarding prediction of lateral pelvic lymph node metastasis and its oncological impact. This review explores the evidence for predicting lateral pelvic lymph node metastasis and survival in locally advanced rectal cancer.
View Article and Find Full Text PDFFemale Sexual Health and Cancer.
Clin Obstet Gynecol
March 2025
Adult Survivorship Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
As the majority of female cancer survivors can now expect to live long lives beyond cancer diagnosis and treatment, there is a growing need to address the significant late effects of treatment. Unfortunately, sexual health remains a primary concern that often goes unaddressed among female cancer survivors. Sexual dysfunction is one of the most common and distressing effects of treatment.
View Article and Find Full Text PDFEvaluation and Treatment of Sexual Pain Disorders.
Clin Obstet Gynecol
March 2025
Centers for Vulvovaginal Disorders, Washington, District of Columbia.
Pain that occurs during sexual activity is highly prevalent during a woman's lifetime, affecting ∼15% of women. The etiology of dyspareunia is multifactorial. Therefore, treatment must be individualized.
View Article and Find Full Text PDFNovel Pharmacologic Treatments of Female Sexual Dysfunction.
Clin Obstet Gynecol
March 2025
Department of Psychiatry & Neurobehavioral Sciences.
This review evaluates pharmacologic treatments for female sexual dysfunction (FSD), focusing on hypoactive sexual desire disorder (HSDD). We provide clinically relevant applications for Food and Drug Administration (FDA)-approved medications (flibanserin and bremelanotide) and investigational therapies (Lorexys and testosterone combinations). Detailed study outcomes, safety profiles, and clinical strategies guide clinicians in appropriate diagnosis, patient selection, expectation setting, side effect management, and patient education, improving treatment outcomes and patient satisfaction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!